PhillyPharma Archive: March, 2012

GSK explains R&D approach

Comment icon 0 Comments
GlaxoSmithKline leaders in research and development presented more specifics Thursday about their relatively new (2008) process for organizing... Read more

M&A in the pharma air

Comment icon 0 Comments
The mergers-and-acquisitions market has been slow for the last couple years, but two possible mergers are in the pharmaceutical air. Actually... Read more

Pfizer breakup, in the Abbott mode?

Comment icon 0 Comments
Pfizer said in July that it was shopping its animal and nutrition units to determine what price it could get for them, all under the usual... Read more

AstraZeneca's Seroquel going generic quicker

Comment icon 0 Comments
The last week was not good for AstraZeneca profits derived through Seroquel as courts on both sides of the Atlantic said patents giving market... Read more

J&J tried, failed to squeeze whistle blower in Texas Medicaid case

Comment icon 0 Comments
A Texas judge Tuesday approved the $158 million settlement between Johnson & Johnson and the state of Texas over allegations that J&J's... Read more

'Bright light' helps expose problems, Texas Medicaid chief says

Comment icon 0 Comments
A trial is scheduled to start Monday in Little Rock, Ark., in which the state of Arkansas will try to prove that Johnson & Johnson's Janssen... Read more

Pharma business model broken, survey says

Comment icon 0 Comments
Nearly 70 percent of pharmaceutical leaders say that the business model for companies selling drugs is broken and needs remodeling, according... Read more

Pa. BIO hands out awards

Comment icon 0 Comments
Pennsylvania Bio, the trade association representing Pennsylvania’s life science industry, held its annual awards dinner Tuesday night... Read more